Discovery of mycotoxin alternariol as a potential lead compound targeting xanthine oxidase

Xanthine oxidase (XO) catalyzes the oxidation of hypoxanthine to xanthine, which is further converted to uric acid. The excessive production or reduced excretion of the purine terminal metabolite may lead to hyperuricemia. In our ongoing search for new xanthine oxidase inhibitors, 14 endophytic fungi were isolated for the first time from a medicinal plant Callicarpa kwangtungensis Chun, and the ethyl acetate extracts of their culture filtrates were screened for XO inhibitory activity. The extract from an endophytic fungus, characterized as Alternaria alternata GDZZ-J6, exhibited the most potent inhibition of XO. Further fractionation of its secondary metabolites led to the isolation of six compounds. Among them, mycotoxin alternariol (AOH), a dibenzo-α-pyrone derivative, had strong inhibitory activity on XO, and the IC₅₀ value was 0.23 ± 0.01 μM. The potency of XO inhibition by AOH was >12-fold higher as compared to allopurinol (2.98 ± 0.07 μM), a XO inhibitor that has been used clinically. The IC₅₀ values of three dibenzo-α-pyrones from gut microbial metabolites of ellagic acid, urolithins A, B, and C, against XO were further compared, and their structure-activity relationships were discussed. Inhibition kinetic analysis by double-reciprocal Lineweaver-Burk plots demonstrated that AOH was an uncompetitive inhibitor. Follow-up docking studies showed that Gln957, Lys1257, and Phe1153 played an important role by forming hydrogen bonds with AOH. Our findings suggest that AOH may be used as a lead compound for further modification to develop future drug for treating hyperuricemia.